- Home
- MGIC vs CANF Comparison
MGIC vs CANF Comparison
Compare MGIC & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- CANF
- Stock Information
- Founded
- MGIC 1983
- CANF 1994
- Country
- MGIC Israel
- CANF Israel
- Employees
- MGIC N/A
- CANF N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- CANF Health Care
- Exchange
- MGIC Nasdaq
- CANF Nasdaq
- Market Cap
- MGIC N/A
- CANF 7.9M
- IPO Year
- MGIC 1991
- CANF N/A
- Fundamental
- Price
- MGIC $13.30
- CANF $1.20
- Analyst Decision
- MGIC Buy
- CANF Strong Buy
- Analyst Count
- MGIC 2
- CANF 2
- Target Price
- MGIC $16.00
- CANF $14.00
- AVG Volume (30 Days)
- MGIC 58.7K
- CANF 413.8K
- Earning Date
- MGIC 05-15-2025
- CANF 04-29-2025
- Dividend Yield
- MGIC 4.25%
- CANF N/A
- EPS Growth
- MGIC N/A
- CANF N/A
- EPS
- MGIC 0.75
- CANF N/A
- Revenue
- MGIC $552,520,000.00
- CANF $674,000.00
- Revenue This Year
- MGIC $7.53
- CANF $461.72
- Revenue Next Year
- MGIC $4.89
- CANF N/A
- P/E Ratio
- MGIC $17.73
- CANF N/A
- Revenue Growth
- MGIC N/A
- CANF N/A
- 52 Week Low
- MGIC $9.51
- CANF $1.22
- 52 Week High
- MGIC $14.24
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- MGIC 53.43
- CANF 37.12
- Support Level
- MGIC $11.98
- CANF $1.22
- Resistance Level
- MGIC $13.43
- CANF $1.82
- Average True Range (ATR)
- MGIC 0.41
- CANF 0.13
- MACD
- MGIC 0.02
- CANF -0.02
- Stochastic Oscillator
- MGIC 90.41
- CANF 3.13
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).